Total Prevalence of Uterine Fibroids per 100 Women Aged 20-54 in 2020 and 2040
Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Uterine Fibroids over the Next 20 Yearsttttttttt
Analysis of Total Prevalent Cases of Uterine Fibroids by Diagnosed and Drug-Treated Status
Total Prevalent Cases
Diagnosed Prevalent Cases of Uterine Fibroids
Diagnosed Incident Cases
Drug-Treated Prevalent Cases of Uterine Fibroids
Lifetime DALYs Gained
Studies Included in the Analysis of Uterine Fibroids
Studies Excluded from the Analysis of Uterine Fibroids
Risk/Protective Factors for Uterine Fibroids
Julie Davis, M.P.H.,is an associate epidemiologist at Clarivate. Previously, she was a research assistant at Tufts Medical Center, where she studied accelerated osteoarthritis and other rheumatic diseases. She also has experience working with zoonotic disease transmission and excess mortality in Puerto Rico stemming from Hurricane Maria. She was part of the Health Emergencies team at the Pan American Health Organization, working on disaster preparedness and disease risk assessments. Ms. Davis received her M.P.H. in global health epidemiology and disease control from George Washington University and holds a bachelor’s degree in health sciences from James Madison University.
Oliver Blandy, M.Sc.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.